Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Nephrol. doi: /nrneph

Published byΕρατώ Βούλγαρης Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Nephrol. doi: /nrneph"— Presentation transcript:

1 Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.60
Figure 2 Pathological consequences of high alkaline phosphatase (ALP) levels Figure 2 | Pathological consequences of high alkaline phosphatase (ALP) levels. a | Cardiovascular dysfunction, chronic kidney disease, genetic factors and bone disease result in increased circulating expression of alkaline phosphatase, tissue-nonspecific isozyme (TNALP)[Au:OK?]. This increasd expression of TNALP is associated with increased mortality and cardiovascular events via mechanisms that involve vascular calcification, endothelial dysfunction, and inflammation. Interventional strategies to reduce TNALP activity include direct ALP inhibitors; epigenetic inhibitors of TNALP expression such as bromodomain and extra-terminal motif (BET) inhibitors; calcimimetic molecules; and vitamin D analogues. b | Elevation of the levels of intestinal-type alkaline phosphatase (IALP) and TNALP owing to sepsis and/or acute inflammation can lead to endotoxin and nucleotide detoxification, cytokine inactivation and reduced oxidative stress, which protect the kidney from inflammatory damage. Similarly, systemic administration of IALP, placental-type alkaline phosphatase (PALP) or chimeric IALP/PALP can exert nephroprotective and anti-inflammatory effects in sepsis and after cardiac surgery. Haarhaus, M. et al. (2017) Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Nat. Rev. Nephrol. doi: /nrneph"

Similar presentations

Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.

Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).

Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 6 Differences in glycaemic control with the study drug

Figure 6 Differences in glycaemic control with the study drug
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
SAVE: Risk of total mortality associated with reduced kidney function

SAVE: Risk of total mortality associated with reduced kidney function
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 1 Types of coronary artery calcification

Figure 1 Types of coronary artery calcification
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.
Figure 3 The fat–intestine–kidney axis

Figure 3 The fat–intestine–kidney axis

Similar presentations

Ads by Google